A citation-based method for searching scientific literature

Thomas A Zelniker, David A Morrow, Ofri Mosenzon, Erica L Goodrich, Petr Jarolim, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John Wilding, Christoph Bode, Basil S Lewis, Ingrid Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Itamar Raz, Marc S Sabatine, Stephen D Wiviott. Eur J Heart Fail 2021
Times Cited: 5







List of co-cited articles
8 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
80

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
492
60

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
812
60

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
40

High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure.
Alberto Aimo, James L Januzzi, Giuseppe Vergaro, Andrea Ripoli, Roberto Latini, Serge Masson, Michela Magnoli, Inder S Anand, Jay N Cohn, Luigi Tavazzi,[...]. Int J Cardiol 2019
14
40

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
40

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
370
40

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Eric J Velazquez, David A Morrow, Adam D DeVore, Carol I Duffy, Andrew P Ambrosy, Kevin McCague, Ricardo Rocha, Eugene Braunwald. N Engl J Med 2019
310
40

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.
Natriuretic Peptides Studies Collaboration, Peter Willeit, Stephen Kaptoge, Paul Welsh, Adam Butterworth, Rajiv Chowdhury, Sarah Spackman, Lisa Pennells, Pei Gao, Stephen Burgess,[...]. Lancet Diabetes Endocrinol 2016
90
20

Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance.
Hilary Chatterton, Tricia Younger, Alastair Fischer, Kamlesh Khunti. BMJ 2012
57
20

Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus.
David A McAllister, Stephanie H Read, Jan Kerssens, Shona Livingstone, Stuart McGurnaghan, Pardeep Jhund, John Petrie, Naveed Sattar, Colin Fischbacher, Soren Lund Kristensen,[...]. Circulation 2018
59
20

Cardiac Troponin T and Troponin I in the General Population.
Paul Welsh, David Preiss, Caroline Hayward, Anoop S V Shah, David McAllister, Andrew Briggs, Charles Boachie, Alex McConnachie, Sandosh Padmanabhan, Claire Welsh,[...]. Circulation 2019
55
20

N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS.
Paul Welsh, Orla Doolin, Peter Willeit, Chris Packard, Peter Macfarlane, Stuart Cobbe, Vilmundur Gudnason, Emanuele Di Angelantonio, Ian Ford, Naveed Sattar. Eur Heart J 2013
41
20

Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
James L Januzzi, Jialin Xu, JingWei Li, Wayne Shaw, Richard Oh, Michael Pfeifer, Javed Butler, Naveed Sattar, Kenneth W Mahaffey, Bruce Neal,[...]. J Am Coll Cardiol 2020
11
20

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
290
20

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck,[...]. JAMA Cardiol 2021
51
20

Heart failure with preserved ejection fraction: from mechanisms to therapies.
Carolyn S P Lam, Adriaan A Voors, Rudolf A de Boer, Scott D Solomon, Dirk J van Veldhuisen. Eur Heart J 2018
127
20


Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Danúbia Silva Dos Santos, Juliano Z Polidoro, Flávio A Borges-Júnior, Adriana C C Girardi. Am J Physiol Cell Physiol 2020
11
20

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
Akira Sezai, Hisakuni Sekino, Satoshi Unosawa, Makoto Taoka, Shunji Osaka, Masashi Tanaka. Cardiovasc Diabetol 2019
17
20

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
345
20

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
259
20


Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.
Ian J Neeland, Darren K McGuire, Robert Chilton, Susanne Crowe, Søren S Lund, Hans J Woerle, Uli C Broedl, Odd Erik Johansen. Diab Vasc Dis Res 2016
79
20



Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
Edoardo Bertero, Leticia Prates Roma, Pietro Ameri, Christoph Maack. Cardiovasc Res 2018
64
20


Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
239
20

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity.
Ningning Wan, Asadur Rahman, Hirofumi Hitomi, Akira Nishiyama. Front Endocrinol (Lausanne) 2018
35
20

Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor.
Tadahiro Shimazu, Matthew D Hirschey, John Newman, Wenjuan He, Kotaro Shirakawa, Natacha Le Moan, Carrie A Grueter, Hyungwook Lim, Laura R Saunders, Robert D Stevens,[...]. Science 2013
715
20

The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Takao Sato, Yoshifusa Aizawa, Sho Yuasa, Shohei Kishi, Koichi Fuse, Satoshi Fujita, Yoshio Ikeda, Hitoshi Kitazawa, Minoru Takahashi, Masahito Sato,[...]. Cardiovasc Diabetol 2018
102
20

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister. Clin Pharmacol Ther 2009
266
20

Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins.
S D Yan, A M Schmidt, G M Anderson, J Zhang, J Brett, Y S Zou, D Pinsky, D Stern. J Biol Chem 1994
981
20

Uric acid and risk of heart failure: a systematic review and meta-analysis.
He Huang, Baotao Huang, Yulin Li, Yan Huang, Jing Li, Hongmei Yao, Xianchao Jing, Jianrong Chen, Ji Wang. Eur J Heart Fail 2014
130
20



Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
245
20

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Giulia Ferrannini, Thomas Hach, Susanne Crowe, Arjun Sanghvi, Kevin D Hall, Ele Ferrannini. Diabetes Care 2015
170
20

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
177
20

Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Seok Joon Shin, Sungjin Chung, Soo Jung Kim, Eun-Mi Lee, Young-Hye Yoo, Ji-Won Kim, Yu-Bae Ahn, Eun-Sook Kim, Sung-Dae Moon, Myung-Jun Kim,[...]. PLoS One 2016
74
20

Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival.
Jeffrey M Testani, Jennifer Chen, Brian D McCauley, Stephen E Kimmel, Richard P Shannon. Circulation 2010
417
20

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
608
20

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
M V Karg, A Bosch, D Kannenkeril, K Striepe, C Ott, M P Schneider, F Boemke-Zelch, P Linz, A M Nagel, J Titze,[...]. Cardiovasc Diabetol 2018
67
20

Chronic inhibition of Na+/H+-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure.
Antonius Baartscheer, Cees A Schumacher, Marcel M G J van Borren, Charly N W Belterman, Ruben Coronel, Tobias Opthof, Jan W T Fiolet. Cardiovasc Res 2005
87
20

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
20


What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
Ross T Campbell, Pardeep S Jhund, Davide Castagno, Nathaniel M Hawkins, Mark C Petrie, John J V McMurray. J Am Coll Cardiol 2012
121
20

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court,[...]. Health Technol Assess 2017
28
20

Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.
J Brett, A M Schmidt, S D Yan, Y S Zou, E Weidman, D Pinsky, R Nowygrod, M Neeper, C Przysiecki, A Shaw. Am J Pathol 1993
622
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.